BROOMFIELD, Colo., Nov. 22, 2011 /PRNewswire/ -- Biodesix today announced that results from a prospectively designed, retrospective analysis of serum samples from the phase III study, EGF30008, will be presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). The purpose of the study was to evaluate the ability of the diagnostic test, VeriStrat, to predict patient outcomes following treatment with either Femara ® or Femara in combination with Tykerb ® in patients with metastatic breast cancer.
VeriStrat, a blood-based proteomic test, is currently used by physicians to help them guide treatment for patients with previously treated advanced non-small cell lung cancer (NSCLC). The test identifies patients who are likely to have good or poor survival outcomes following treatment with EGFR-TKIs, such as Tarceva®. VeriStrat has been evaluated in several lung cancer trials, including the phase III registrational trial of Tarceva in advanced NSCLC.
The data will be presented during General Session 1 at the SABCS in San Antonio, TX on Wednesday, December 7th, 2011 at 10:15 AM CST.
For more information on the location of the presentation, visit www.sabcs.org.
About VeriStrat
VeriStrat is a serum proteomic test currently available for patients with advanced NSCLC. The test identifies patients who are likely to have good or poor outcomes after treatment with epidermal growth factor receptor inhibitors (EGFRIs). Samples are processed in Biodesix' CLIA accredited laboratory and results are typically reported within 72 hours of sample shipment. VeriStrat has been validated in clinical studies with over 1500 patients. For more information on VeriStrat or to order VeriStrat, visit www.VeriStratSupport.com or call the VeriStrat Support Hotline at 1-866-432-5930.
About Biodesix
Biodesix is a personalized medicine company focused on the development of diagnostic products that inform treatment decisions and improve patient care. The Company's goal is to give physicians more information about the patient and their disease; understanding the clinically meaningful information contained within each patient's molecular profile leads to better care and better outcomes. The Company's unique approach is based on ProTS®, proprietary technology which exploits the power of mass spectrometry and enables the discovery of specific molecular profiles. Biodesix collaborates with clinical investigators to address critical clinical questions, and partners with biotechnology and pharmaceutical companies to develop diagnostics to select patients most likely to benefit from novel therapies. For more information about Biodesix, please visit www.Biodesix.com.
Femara® is a registered trademark of Novartis International AG.
Tykerb® is a registered trademark of the GlaxoSmithKline group of companies in the United States and the countries outside of Europe.
Tarceva® is a registered trademark of OSI Pharmaceuticals, LLC, a member of the Astellas Pharma Global Development Inc. group of companies.
This press release contains statements that are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the Company's inability to further identify, develop and achieve commercial success for products and technologies; the risk that the Company's financial resources will be insufficient to meet the Company's business objectives; uncertainties relating to the regulatory approval process and changes in relationships with strategic partners. We disclaim any intent or obligation to update these forward-looking statements.
SOURCE Biodesix
